DOCSLIB.ORG

ADEPT*Preview

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADEPT*Preview 15/2006 13 Apr/avr 2006 PCT Gazette - Section III - Gazette du PCT 10667 SECTION III WEEKLY INDEXES INDEX HEBDOMADAIRES INTERNATIONAL APPLICATION NUMBERS AND CORRESPONDING INTERNATIONAL PUBLICATION NUMBERS NUMÉROS DES DEMANDES INTERNATIONALES ET NUMÉROS DE PUBLICATION INTERNATIONALE CORRESPONDANTS International International International International International International Application Publication Application Publication Application Publication Numbers Numbers Numbers Numbers Numbers Numbers Numéros des Numéros de Numéros des Numéros de Numéros des Numéros de demandes publication demandes publication demandes publication internationales internationale internationales internationale internationales internationale AT AZ CH PCT/AT2005/000324 WO 2006/037136 PCT/AZ2004/000002 WO 2006/037190 PCT/CH2005/000430 WO 2006/037239 PCT/AT2005/000383 WO 2006/037137 PCT/CH2005/000449 WO 2006/037240 PCT/AT2005/000385 WO 2006/037138 BE PCT/CH2005/000495 WO 2006/037241 PCT/AT2005/000386 WO 2006/037139 PCT/BE2004/000140 WO 2006/037191 PCT/CH2005/000526 WO 2006/037242 PCT/AT2005/000389 WO 2006/037140 PCT/BE2005/000034 WO 2006/037192 PCT/CH2005/000556 WO 2006/037243 PCT/AT2005/000390 WO 2006/037141 PCT/BE2005/000142 WO 2006/037193 PCT/CH2005/000558 WO 2006/037244 PCT/AT2005/000394 WO 2006/037142 PCT/CH2005/000563 WO 2006/037245 PCT/AT2005/000398 WO 2006/037143 BR PCT/CH2005/000564 WO 2006/037246 PCT/AT2005/000399 WO 2006/037144 PCT/BR2004/000189 WO 2006/037194 PCT/CH2005/000566 WO 2006/037247 PCT/AT2005/000400 WO 2006/037145 PCT/BR2004/000193 WO 2006/037195 PCT/CH2005/000571 WO 2006/037248 PCT/BR2005/000208 WO 2006/037196 PCT/CH2005/000573 WO 2006/037249 AU PCT/BR2005/000209 WO 2006/037197 PCT/CH2005/000576 WO 2006/037250 PCT/AU2004/001352 WO 2006/037146 PCT/BR2005/000210 WO 2006/037198 PCT/CH2005/000580 WO 2006/037251 PCT/AU2004/001354 WO 2006/037147 PCT/BR2005/000213 WO 2006/037199 PCT/CH2005/000582 WO 2006/037252 PCT/AU2005/001051 WO 2006/037148 PCT/BR2005/000219 WO 2006/037200 PCT/CH2005/000583 WO 2006/037253 PCT/AU2005/001417 WO 2006/037149 PCT/CH2005/000585 WO 2006/037254 PCT/AU2005/001434 WO 2006/037150 CA PCT/CH2005/000586 WO 2006/037255 PCT/AU2005/001438 WO 2006/037151 PCT/CA2004/001770 WO 2006/037201 PCT/AU2005/001501 WO 2006/037152 PCT/CA2004/002081 WO 2006/037202 CN PCT/AU2005/001503 WO 2006/037153 PCT/CA2005/000498 WO 2006/037203 PCT/CN2004/001139 WO 2006/037256 PCT/AU2005/001504 WO 2006/037154 PCT/CA2005/000526 WO 2006/037204 PCT/CN2004/001144 WO 2006/037257 PCT/AU2005/001505 WO 2006/037155 PCT/CA2005/000879 WO 2006/037205 PCT/CN2004/001145 WO 2006/037258 PCT/AU2005/001506 WO 2006/037156 PCT/CA2005/001075 WO 2006/037206 PCT/CN2005/000250 WO 2006/037259 PCT/AU2005/001507 WO 2006/037157 PCT/CA2005/001354 WO 2006/037207 PCT/CN2005/000433 WO 2006/037260 PCT/AU2005/001509 WO 2006/037158 PCT/CA2005/001431 WO 2006/037208 PCT/CN2005/001100 WO 2006/037261 PCT/AU2005/001510 WO 2006/037159 PCT/CA2005/001486 WO 2006/037209 PCT/CN2005/001451 WO 2006/037262 PCT/AU2005/001511 WO 2006/037160 PCT/CA2005/001487 WO 2006/037210 PCT/CN2005/001526 WO 2006/037263 PCT/AU2005/001512 WO 2006/037161 PCT/CA2005/001502 WO 2006/037211 PCT/CN2005/001542 WO 2006/037264 PCT/AU2005/001513 WO 2006/037162 PCT/CA2005/001503 WO 2006/037212 PCT/CN2005/001584 WO 2006/037265 PCT/AU2005/001514 WO 2006/037163 PCT/CA2005/001505 WO 2006/037213 PCT/CN2005/001588 WO 2006/037266 PCT/AU2005/001517 WO 2006/037164 PCT/CA2005/001507 WO 2006/037214 PCT/CN2005/001592 WO 2006/037267 PCT/AU2005/001518 WO 2006/037165 PCT/CA2005/001508 WO 2006/037215 PCT/CN2005/001597 WO 2006/037268 PCT/AU2005/001519 WO 2006/037166 PCT/CA2005/001509 WO 2006/037216 PCT/CN2005/001599 WO 2006/037269 PCT/AU2005/001520 WO 2006/037167 PCT/CA2005/001511 WO 2006/037217 PCT/CN2005/001610 WO 2006/037270 PCT/AU2005/001521 WO 2006/037168 PCT/CA2005/001512 WO 2006/037218 PCT/CN2005/001614 WO 2006/037271 PCT/AU2005/001522 WO 2006/037169 PCT/CA2005/001513 WO 2006/037219 PCT/CN2005/001624 WO 2006/037272 PCT/AU2005/001524 WO 2006/037170 PCT/CA2005/001519 WO 2006/037220 PCT/CN2005/001626 WO 2006/037273 PCT/AU2005/001525 WO 2006/037171 PCT/CA2005/001521 WO 2006/037221 PCT/CN2005/001629 WO 2006/037274 PCT/AU2005/001526 WO 2006/037172 PCT/CA2005/001522 WO 2006/037222 PCT/CN2005/001639 WO 2006/037275 PCT/AU2005/001527 WO 2006/037173 PCT/CA2005/001523 WO 2006/037223 PCT/CN2005/001640 WO 2006/037276 PCT/AU2005/001529 WO 2006/037174 PCT/CA2005/001525 WO 2006/037224 PCT/CN2005/001641 WO 2006/037277 PCT/AU2005/001530 WO 2006/037175 PCT/CA2005/001526 WO 2006/037225 PCT/CN2005/001648 WO 2006/037278 PCT/AU2005/001531 WO 2006/037176 PCT/CA2005/001527 WO 2006/037226 PCT/AU2005/001532 WO 2006/037177 PCT/CA2005/001528 WO 2006/037227 CY PCT/AU2005/001533 WO 2006/037178 PCT/CA2005/001529 WO 2006/037228 PCT/CY2005/000003 WO 2006/037279 PCT/AU2005/001535 WO 2006/037179 PCT/CA2005/001535 WO 2006/037229 PCT/AU2005/001537 WO 2006/037180 PCT/CA2005/001536 WO 2006/037230 CZ PCT/AU2005/001539 WO 2006/037181 PCT/CA2005/001537 WO 2006/037231 PCT/CZ2005/000018 WO 2006/037280 PCT/AU2005/001540 WO 2006/037182 PCT/CA2005/001538 WO 2006/037232 PCT/CZ2005/000033 WO 2006/037281 PCT/AU2005/001541 WO 2006/037183 PCT/CA2005/001540 WO 2006/037233 PCT/CZ2005/000042 WO 2006/037282 PCT/AU2005/001543 WO 2006/037184 PCT/CA2005/001542 WO 2006/037234 PCT/AU2005/001548 WO 2006/037185 PCT/CA2005/001549 WO 2006/037235 DE PCT/AU2005/001550 WO 2006/037186 PCT/CA2005/001556 WO 2006/037236 PCT/DE2004/002173 WO 2006/037283 PCT/AU2005/001551 WO 2006/037187 PCT/CA2005/001557 WO 2006/037237 PCT/DE2005/000946 WO 2006/037284 PCT/AU2005/001552 WO 2006/037188 PCT/CA2005/001575 WO 2006/037238 PCT/DE2005/001607 WO 2006/037285 PCT/AU2005/001553 WO 2006/037189 PCT/DE2005/001640 WO 2006/037286 PCT/DE2005/001644 WO 2006/037287 15/2006 10668 PCT Gazette - Section III - Gazette du PCT 13 Apr/avr 2006 International Application Numbers and Corresponding International Publication Numbers (Continued) Numéros des demandes internationales et numéros de publication internationale correspondants (Suite) International International International International International International Application Publication Application Publication Application Publication Numbers Numbers Numbers Numbers Numbers Numbers Numéros des Numéros de Numéros des Numéros de Numéros des Numéros de demandes publication demandes publication demandes publication internationales internationale internationales internationale internationales internationale DE EP EP PCT/DE2005/001681 WO 2006/037288 PCT/EP2004/010962 WO 2006/037355 PCT/EP2005/009780 WO 2006/037430 PCT/DE2005/001692 WO 2006/037289 PCT/EP2004/011005 WO 2006/037356 PCT/EP2005/009781 WO 2006/037431 PCT/DE2005/001693 WO 2006/037290 PCT/EP2004/011038 WO 2006/037357 PCT/EP2005/009813 WO 2006/037432 PCT/DE2005/001704 WO 2006/037291 PCT/EP2004/011045 WO 2006/037358 PCT/EP2005/009814 WO 2006/037433 PCT/DE2005/001736 WO 2006/037292 PCT/EP2004/011056 WO 2006/037359 PCT/EP2005/009839 WO 2006/037434 PCT/DE2005/001743 WO 2006/037293 PCT/EP2004/011065 WO 2006/037360 PCT/EP2005/009840 WO 2006/037435 PCT/DE2005/001744 WO 2006/037294 PCT/EP2004/011110 WO 2006/037361 PCT/EP2005/009878 WO 2006/037436 PCT/DE2005/001745 WO 2006/037295 PCT/EP2004/011166 WO 2006/037362 PCT/EP2005/009880 WO 2006/037437 PCT/DE2005/001746 WO 2006/037296 PCT/EP2004/011177 WO 2006/037363 PCT/EP2005/009888 WO 2006/037438 PCT/DE2005/001753 WO 2006/037297 PCT/EP2004/011204 WO 2006/037364 PCT/EP2005/009900 WO 2006/037439 PCT/DE2005/001759 WO 2006/037298 PCT/EP2004/011225 WO 2006/037365 PCT/EP2005/009946 WO 2006/037440 PCT/DE2005/001760 WO 2006/037299 PCT/EP2004/011266 WO 2006/037366 PCT/EP2005/009959 WO 2006/037441 PCT/DE2005/001761 WO 2006/037300 PCT/EP2004/011326 WO 2006/037367 PCT/EP2005/009961 WO 2006/037442 PCT/DE2005/001762 WO 2006/037301 PCT/EP2004/011361 WO 2006/037368 PCT/EP2005/009962 WO 2006/037443 PCT/DE2005/001763 WO 2006/037302 PCT/EP2004/011431 WO 2006/037369 PCT/EP2005/009966 WO 2006/037444 PCT/DE2005/001764 WO 2006/037303 PCT/EP2004/013494 WO 2006/037370 PCT/EP2005/009972 WO 2006/037445 PCT/DE2005/001765 WO 2006/037304 PCT/EP2004/014403 WO 2006/037371 PCT/EP2005/009973 WO 2006/037446 PCT/DE2005/001766 WO 2006/037305 PCT/EP2004/052390 WO 2006/037372 PCT/EP2005/009982 WO 2006/037447 PCT/DE2005/001767 WO 2006/037306 PCT/EP2004/052401 WO 2006/037373 PCT/EP2005/009992 WO 2006/037448 PCT/DE2005/001768 WO 2006/037307 PCT/EP2004/052442 WO 2006/037374 PCT/EP2005/009998 WO 2006/037449 PCT/DE2005/001769 WO 2006/037308 PCT/EP2004/052452 WO 2006/037375 PCT/EP2005/010000 WO 2006/037450 PCT/DE2005/001770 WO 2006/037309 PCT/EP2004/052454 WO 2006/037376 PCT/EP2005/010003 WO 2006/037451 PCT/DE2005/001771 WO 2006/037310 PCT/EP2004/052472 WO 2006/037377 PCT/EP2005/010026 WO 2006/037452 PCT/DE2005/001772 WO 2006/037311 PCT/EP2004/052486 WO 2006/037378 PCT/EP2005/010052 WO 2006/037453 PCT/DE2005/001776 WO 2006/037312 PCT/EP2004/052487 WO 2006/037379 PCT/EP2005/010053 WO 2006/037454 PCT/DE2005/001780 WO 2006/037313 PCT/EP2004/052832 WO 2006/037380 PCT/EP2005/010068 WO 2006/037455 PCT/DE2005/001784 WO 2006/037314 PCT/EP2004/053703 WO 2006/037381 PCT/EP2005/010078 WO 2006/037456 PCT/DE2005/001788 WO 2006/037315 PCT/EP2005/000280 WO 2006/037382 PCT/EP2005/010096 WO 2006/037457 PCT/DE2005/001789 WO 2006/037316 PCT/EP2005/003615 WO 2006/037383 PCT/EP2005/010112 WO 2006/037458 PCT/DE2005/001790 WO 2006/037317 PCT/EP2005/003962 WO 2006/037384 PCT/EP2005/010146 WO 2006/037459 PCT/DE2005/001792 WO 2006/037318 PCT/EP2005/005677 WO 2006/037385 PCT/EP2005/010147 WO 2006/037460 PCT/EP2005/007005 WO 2006/037386 PCT/EP2005/010150
Load more

Recommended publications
  • 2015 Annual Report
    ANNUAL REPORT 2015 MARCH 2016 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer This year at Johnson & Johnson, we are proud this aligned with our values. Our Board of WRITTEN OVER to celebrate 130 years of helping people Directors engages in a formal review of 70 YEARS AGO, everywhere live longer, healthier and happier our strategic plans, and provides regular OUR CREDO lives. As I reflect on our heritage and consider guidance to ensure our strategy will continue UNITES & our future, I am optimistic and confident in the creating better outcomes for the patients INSPIRES THE long-term potential for our business. and customers we serve, while also creating EMPLOYEES long-term value for our shareholders. OF JOHNSON We manage our business using a strategic & JOHNSON. framework that begins with Our Credo. Written OUR STRATEGIES ARE BASED ON over 70 years ago, it unites and inspires the OUR BROAD AND DEEP KNOWLEDGE employees of Johnson & Johnson. It reminds OF THE HEALTH CARE LANDSCAPE us that our first responsibility is to the patients, IN WHICH WE OPERATE. customers and health care professionals who For 130 years, our company has been use our products, and it compels us to deliver driving breakthrough innovation in health on our responsibilities to our employees, care – from revolutionizing wound care in communities and shareholders. the 1880s to developing cures, vaccines and treatments for some of today’s most Our strategic framework positions us well pressing diseases in the world. We are acutely to continue our leadership in the markets in aware of the need to evaluate our business which we compete through a set of strategic against the changing health care environment principles: we are broadly based in human and to challenge ourselves based on the health care, our focus is on managing for the results we deliver.
    [Show full text]
  • 2Nd Quarter 2015 Earnings Call Presentation
    2nd Quarter 2015 Earnings Call Presentation July 14, 2015 1 Louise Mehrotra Vice President Investor Relations 2 Note on Forward-Looking Statements These presentations contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges and uncertainties inherent in new product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including global health care reforms; trends toward health
    [Show full text]
  • Page 1 of 27 MD Consult: Diabetes, Diet For: Comprehensive Version
    MD Consult: Diabetes, Diet for: Comprehensive Version: Patient Education Page 1 of 27 Boise Kidney and Hypertension 3525 East Louise Rd Ste 100 Meridian, ID 83642 208-846-8335 Diabetes diet Highlights Lifestyle Changes Essential for People at Risk for Diabetes Lifestyle interventions that include weight loss, dietary changes, and increased physical activity can definitely help prevent or delay the progression to diabetes among at-risk people, suggest several recent studies. Weight loss through diet and exercise is especially important for overweight people with pre-diabetes. Grain Fiber Important for Diabetes Prevention Eating whole-grain, fiber-rich, cereal foods may help reduce the risk of developing type 2 diabetes, indicates a 2007 study in the Archives of Internal Medicine. In the study, people who consumed the most fiber from grains and cereals had a 33% lower risk of developing diabetes than people with the lowest fiber intakes. The study also found an association between high magnesium intake and reduced diabetes risk. Although fruits and vegetables also contain fiber, they did not appear to affect diabetes risk. Low-Fat Dairy Products Incorporating low-fat dairy products (such as yogurt and milk) into a healthy diet may help reduce diabetes risk for women, suggests a study in Diabetes Care. Beware of Internet Dietary Supplement Scams In 2006, the FDA alerted consumers not to be misled by dietary supplements advertised on the Internet as treatments or cures for diabetes. These products have not been scientifically studied or approved. Low-Glycemic Index Diets Food low on the glycemic index -- such as whole grains, fruits, lentils, and soybeans -- can help promote weight loss and heart health.
    [Show full text]
  • ODWB 16 0.Pdf
    PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Thursday, Kathleen Elliott, Pediatrics/Geriatrics – Take 42824 July 21, OD Your Pick (2 hrs) 2 hours 2016 GO Implications of Selected Corneal Jeffrey Urness, 49516 2 hours Conditions on Refractive Surgery OD (2 hrs) AS Therapeutic Environment, Diet and Amber Giannoni, Supplements: What Role Do 40852 1 hour OD They Play in Dry Eye Disease? (1 hr) AS Therapeutic Friday, Amber Giannoni, Dry Eye and Systemic Disease 40851 2 hours July 22 OD (2 hrs) SD Therapeutic 49515 Kathleen Elliott, The ABC’s of Pediatric Eye Care 1 hour OD (1 hr) FV John McGreal, New Ideas in Glaucoma 43612 2 hours OD Management (2 hrs) GL Therapeutic Total hours offered: 10 Total hours earned: Name License # Mailing Address ______ Please retain a copy of this stamped form as verification of hours earned. Please be advised that your individual state board makes the final determination of applicable hours. For more information, contact Pacific University College of Optometry, 2043 College Way . Forest Grove, OR 97116 . 503-352-2202 1 of 193 2 of 193 PACIFIC UNIVERSITY COLLEGE OF OPTOMETRY 2016 VICTORIA CONFERENCE July 21 to 24, 2016 Delta Victoria Ocean Point Victoria, B.C. CANADA COPE EVENT #111397 Date Speaker Title COPE Verification Saturday, John McGreal, The Latest Trends in 43497 2 hours July23 OD Contemporary Medicine (2 hrs) PH Therapeutic Non-Surgical Radiofrequency Kathleen Elliott, 46927 2 hours Periocular Soft Tissue OD Rejuvenation (2 hrs) AS Therapeutic 42998 John McGreal, New Tools for the Tool Box 1 hour OD (1 hr) GO Sunday, Jeffrey Urness, 49517 1 hour Bacterial Corneal Ulcers (1 hr) July 24 OD AS Therapeutic 49514 Kathleen Elliott, Pediatric Case Reports: The 1 hour OD Good, Bad and Ugly (1 hr) FV 43552 Amber Giannoni, Setting Up a Dry Eye Practice 1 hour OD (1 hr) PM Jeffrey Urness, Corneal Transplantation Front 40409 2 hours OD to Back, Side to Side.
    [Show full text]
  • Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive
    Pursuit Resources Group Ltd First Floor, 4 Freeport Office Village, Century Drive, Braintree, Essex, CM77 8YG Telephone E-mail Website 01245 362500 [email protected] www.pursuitgroup.co.uk Candidate: 24870 2000 - 2003 South Bank University – • BA (Hons) Business Administration (2:1) 1998 - 2000 Westcliff High School Education: • A-levels: Biology, General Studies, Psychology 1993 - 1998 St. Bernard’s High School • GCSE’s: 10 A-C subjects, including English, Mathematics and Sciences Notice Period: 2 months Salary £38,000 NB: To give you an enhanced understanding of the candidate we have checked the validity of the information and left the CV in its original format. A media marketing manager with 10+ years’ experience delivering multiple cross-media campaigns for high profile brands. With track record of executing communication strategies and client objectives from conception to completion. Employment History: Media Account Director Nov 16 – present • Manage and coordinate a team to create and develop Nestlé’s Water and Nutrition divisions’ annual marketing strategy • in line with business objectives • Utilise a mix of media channels including above and below the line media (TV, OOH, print, radio, digital, social and • product placements) ensuring relevancy to the target audience • Keep up to date with new media innovations, changing media landscape and trends in the industry • Develop consumer and shopper insights to feed into overall media strategy to present back to senior business leaders • Strategise and implement
    [Show full text]
  • Challenges Facing the Branded Drug Industry
    CHAPTER 1 Challenges Facing the Branded Drug Industry In 2004, Capgemini conducted an industry - wide survey on pharmaceutical lifecycle management (LCM) ( “ Increasing the lifetime value of pharmaceuti- cal products, ” Capgemini Vision & Reality Research, 2004). They held a series of interviews with pharmaceutical industry executives, asking them how important LCM had been for their business in the past 5 years and how they expected its importance to change during the coming 5 years. As can be seen in Figure 1.1 , these executives felt that LCM had been important, but 90% predicted that its importance would grow during the 5 years following the publication of the report (2006 – 2010), with 60% expecting it to become much more important. Today, just after the time horizon of this prediction, we can look back and state that it has proven to be very accurate, with more and more attention paid to LCM in company statements, conferences, and industry reports. Why did these executives expect LCM to gain in importance, and why has their prediction proven to be correct? To set the scene for any discussion of LCM of pharmaceuticals, it is essential that one fully understands the challenges facing the branded drug industry. On the one hand, many of these factors are drivers of the increased interest in LCM; on the other hand, some of the factors actively discourage LCM and put into question the sustainability of certain LCM strategies that were suc- cessful in the past. As we see it, the main challenges are the following: • Depleted COPYRIGHTEDnew molecular entity (NME) pipelines/lower MATERIAL R & D effi ciency • Higher development costs • Safety concerns • Tougher environment for pricing, reimbursement, and listing Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand, First Edition.
    [Show full text]
  • Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net
    Johnson & Johnson 1999 Third Quarter Sales Increased 17.9% Net Earnings Rose 14.4% EPS Rose 14.3 NEW BRUNSWICK, N.J., Oct. 19-- Johnson & Johnson (NYSE: JNJ) today announced sales of $6.7 billion and net earnings of $1.1 billion for the third quarter of 1999, increases of 17.9% and 14.4%, respectively, over 1998 third-quarter results. Diluted earnings per share for the third quarter were $.80, up 14.3% from the same period in 1998. The impact of the stronger dollar relative to foreign currencies decreased third-quarter sales by 1.3%. Domestic sales were up 24.1%, while international sales increased 10.7%, reflecting a negative currency impact of 2.9%. "We continue to achieve strong double-digit sales and earnings growth that reflects the strength and vitality of our businesses in all segments and almost all geographic areas," said Ralph S. Larsen, Chairman and Chief Executive Officer. "Of particular note is the impressive performance of our domestic pharmaceutical business." Worldwide pharmaceutical sales of $2.6 billion for the quarter increased 23.9% over the same period in 1998, including 35.7% growth in domestic sales and a 9.5% increase in international sales. International sales gains of 12.6% in local currency were offset by a negative currency impact of 3.1%. Sales growth reflects the strong performance of PROCRIT/EPREX, for the treatment of anemia; RISPERDAL, an antipsychotic medication; DURAGESIC, a transdermal patch for chronic pain; LEVAQUIN, an anti-infective; ULTRAM, an analgesic, and the oral contraceptive line of products. During the quarter, the company announced a $4.9 billion definitive stock-for-stock merger with Centocor, Inc., a leader in monoclonal antibody technology and acute vascular care and immunology products.
    [Show full text]
  • 2014 Annual Report • 1 Management’S Discussion and Analysis of Results of Operations and Financial Condition
    ANNUAL REPORT 2014 MARCH 2015 TO OUR SHAREHOLDERS ALEX GORSKY Chairman, Board of Directors and Chief Executive Officer I am often asked what led me to work in Perhaps there’s no better proof of that than the THERE IS health care and why I chose to spend most success Johnson & Johnson achieved in 2014. NO COMPANY of my career at Johnson & Johnson. From my We delivered solid financial results, with full-year BETTER first job at Janssen, the flagship company of 2014 sales of $74.3 billion and adjusted net POSITIONED our Pharmaceutical segment, to my current earnings of $17.1 billion†, while also continuing TO HELP MEET role as the company’s Chairman and CEO to make investments to accelerate growth for THESE URGENT 25 years later, the answer always begins the long term. NEEDS THAN with Our Credo. JOHNSON & And while I am pleased with our performance, JOHNSON A simple yet powerful document penned we know that we can never rest, because by General Robert Wood Johnson, the son of providing sustainable high-quality health care our founder and our company’s first Chairman, is one of our society’s greatest challenges. Our Credo outlines the Company’s commitments and responsibilities to the people and This is an unprecedented era in human history. communities we touch every day with our The historic aging rate of the world’s population, products and services. For more than 70 years along with a growing middle class around the now, it has served as the moral compass of world, brings dramatically greater demand for Johnson & Johnson – ensuring we never lose higher quality health care; and governments sight of our strong values and the important and health systems must manage this with needs of the many stakeholders we serve.
    [Show full text]
  • Palm Oil Shopping Guide: Current Best Choices
    FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of FOOD Brand Names of Make a Difference RSPO Members RSPO Members RSPO Members RSPO Members RSPO Members for Wild 3 Musketeers Cinnamon Toast Crunch Honey Maid Grahams Mothers Cookies Splenda Orangutans Act II Coffee Mate Hot Pockets Mountain High Yogurt Starburst Adam's PB Country Crock Hungry Jack Muffin Mam Pastries Stouffers Almond Joy Country Time Hunt's Muir Glen Trident Gum BOYCOTTING PALM Altoids Crisco International Delight Nabisco Sun Chips OIL IS NOT THE Arnott's Biscuits Crunch and Munch Jenny Craig Meals Nature Valley SuperMoist Cake Mixes SOLUTION… Aunt Jemima Foods Dean's Dips Jeno's Pizza Near East Sweet Rewards Bars Austin Brand Crackers Doritos Jif PB Nerds Sweet Tarts Supporting Baby Ruth Dove Chocolates Jiffy Pop Nesquik Swiss Miss companies that are Bac Os Dreyer's Jolly Ranchers Nestle Products Tombstone Pizza members of the Baker's Chocolate Edy's Justin's NutButter Nutter Butter Cookies Tostitos RSPO (Roundtable on Balance Bars Egg Beaters Justin's PB Cups Old El Paso Total Cereal Sustainable Palm Oil) Banquet Meals Endangered Species Choc. Keebler Cookies Oreo Cookies Totino's Pizza is the most Barilla Famous Amos Cookies Keebler Crackers Orville Redenbacher's Trix Cereal responsible solution. BelVita Fiber One Products Kellogg's Products Pam Tuna Helper Ben & Jerry's Ice Cream Fleischmann's Kid Cuisine Parent's Choice Twix Bertolli Frito Lay Kit Kat Parkay Twizzlers For more information Betty Crocker products Folgers Kix Cereal Pasta
    [Show full text]
  • Case 10 Raisio Group and the Benecol Launch*
    CTAC10 4/13/07 17:24 Page 163 case 10 Raisio Group and the Benecol Launch* Case [A]: The Situation in January 1997 During 1996, Raisio Group, a 57-year-old grain-milling company based in Raisio in the south-west of Finland, emerged from obscurity to become the second most valuable public company in Finland (after Nokia) and the focus of worldwide attention. The launch of Benecol, its cholesterol-lowering margarine, at the end of 1995 had attracted the interest of food processors and supermarket groups throughout the world and fueled a surge of investor interest. Demand for the product had outstripped Raisio’s capability to produce the active ingredient in Benecol, stanol ester. On the Helsinki stock market, foreign demand pushed Raisio’s share price from FIM61 at the beginning of the year to FIM288 at the end (after touching FIM322 during the summer).1 CEO Matti Salminen commented: 1996 will go down in the Raisio Group’s history as the “Benecol year” – such was the role of this new cholesterol-reducing margarine in increasing the Group’s visibility and raising its profile in all our sectors of operations. Although we have not been able to meet even the domestic demand for Benecol margarine so far, the product is already known worldwide and great expectations are attached to it. The Benecol phenomenon quintupled the value of our shares, increasing the Group’s capitalization by billions of Finnish marks.2 It was the international prospects for Benecol margarine (and potentially other food products incorporating stanol ester) that had drawn a bevy of stock analysts * This case draws upon an earlier case by Michael H.
    [Show full text]
  • A Topic Modeling Approach to Categorizing API Customer Value Propositions
    A Topic Modeling Approach to Categorizing API Customer Value Propositions by Mohamed Amin A thesis submitted to the Faculty of Graduate and Postdoctoral Affairs in partial fulfillment of the requirements for the degree of Master of Applied Science in Technology Innovation Management Carleton University Ottawa, Ontario Copyright © 2016, Mohamed Amin Abstract Companies increasingly use Application Programming Interfaces (APIs) to create new value propositions in the digital world. However, there is little knowledge about the type of value propositions that public APIs enable companies to provide. Thus, this study analyzes data from 13,829 API descriptions published in programmableweb.com to: (i) identify and categorize current and emerging API customer value propositions, (ii) analyze the evolution of API customer value propositions, and (iii) showcase Topic Modeling as a feasible technique to study API customer value propositions. This research contributes towards API service systems research by: (i) identifying six categories of API customer value propositions, and (ii) revealing a long tail distribution of API customer value propositions that is flattening. ii Acknowledgements I would like to start by thanking my Supervisor, Professor Mika Westerlund, for his guidance, tolerance, and open mind for new ideas and methods. I would also like to thank the TIM faculty: Professor Tony Bailetti, for teaching me what a Customer Value Proposition in the real world means, Professor Michael Weiss, for giving me the fundamental idea behind this research, and Professor Steven Muegge, for teaching me meticulousness in research and writing. Although I may have not met their standards yet, I know I am headed in the right direction.
    [Show full text]
  • 2016 Annual Report
    ANNUAL REPORT 2016 MARCH 2017 TO OUR SHAREHOLDERS ALEX GORSKY Chairman and Chief Executive Officer I’ve worked in the health care industry for Rather, true innovations are the result of WE ARE UNITED nearly 30 years. It’s been both an honor and collaboration. And that collaboration is AND INSPIRED a privilege to work for Johnson & Johnson, driven by a diversity of ideas, individuals BY OUR CREDO, a company that touches the lives of over and disciplines – working together toward WHICH RINGS a billion people every day, around the a common goal. AS TRUE TODAY world. As I look at today’s health care AS IT DID WHEN landscape, it’s incredibly clear that the Today, more than ever, the world needs IT WAS WRITTEN pace of change has never been greater, leaders who are committed to working MORE THAN 70 or frankly, more exciting. together to help bring improved health YEARS AGO. and wellness to every person in every Today’s rapid change brings both corner of the globe. As the world’s largest opportunities and risks for any company and most broadly based health care in health care, and we are prepared company, we are uniquely positioned to help to address both. There are significant transform global health care; to shine a light challenges to overcome, but the tools, the on the most important issues we are facing; insights, the technologies, the innovations to collaborate across boundaries and – both evolutions and revolutions – all borders; to uncover scientific insights and combine to make today one of the most ideas; and to dedicate resources towards promising times for human health and for creating tomorrow’s breakthroughs.
    [Show full text]